GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novavax (NVAX) reached $8.97 at the closing of the latest trading day, reflecting a +2.51% change compared to its last close.

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax (NVAX) concluded the recent trading session at $8.37, signifying a -3.68% move from its prior day's close.

Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.

The business may not be as strong as its performance this year suggests.

In the latest trading session, Novavax (NVAX) closed at $9.22, marking a -6.07% move from the previous day.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the latest trading session, Novavax (NVAX) closed at $9.71, marking a -1.97% move from the previous day.